ACR component, Physician's Global Assessment of disease activity on a 0 - 100 mm VAS by visit is the first response ACR variable in the ACR pediatric criteria. The VAS scale ranges from no disease activity (0 mm) to very severe disease activity (100 mm). Lower scale indicates decreased disease activity. Change from baseline was calculated by subtracting baseline value from post baseline value.

ACR component, Parent's or Patient's (if appropriate in age)Global Assessment of patient's overall well-being as part of CHAQ on a 0 - 100 mm VAS by visit is the second response variable in the ACR pediatric criteria. The VAS scale ranges from 0-100 mm, from very well (0 mm) to very poor (100 mm). Lower scale indicates improvement of patient's overall well-being. Absolute change is calculated by subtracting baseline value from post baseline value.

Disability Score as part of CHAQ per functional ability score (range from 0 to 3) is one of the variable in the ACR ped criteria. The CHAQ was used to assess physical ability & functional status of patients as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activity categories of daily living: dressing & grooming, arising, eating, walking, reaching, personal hygiene, gripping & other "activities". Subjects choose from 4 responses, ranging from 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) & 3 (unable to do). Standard Disability Index (SDI) was computed by summing up the computed scores for each activity category and dividing by the number of categories answered. The lower the response the more positive the results & the higher the response, the less positive the results. Change from baseline was calculated by subtracting baseline value from post baseline value.

ACR component, Number of joints with active arthritis was assessed as the forth response variables of ACR Pediatric Criteria.

ACR component, Number of joints with limitation of motion is the fifth response variable in the ACR ped criteria.

ACR component, Number of participants having fever is the seventh response variable in the ACR ped criteria.

ACR component, Standardized CRP is the sixth response variable in the ACR ped criteria. CRP values were standardized to a normal range of 0 to 10 mg/L.

Flare was defined by at least 1 of the following: Reappearance of SJIA-related (e.g., not due to infection) fever (> 38°C) lasting for at least 2 consecutive days &/OR Flare according to the JIA pediatric criteria for flare (all criteria must be met): ≥ 30% worsening in at least 3 of the 6 response variables and ≥ 30% improvement in at not more than 1 of the 6 response variables if the physician's or parent's global assessment is 1of 3 response variables used to define flare, worsening of ≥ 20 mm must be present, if the number of active joints or joints with limitation of motion is one of 3 response variables used to define flare, worsening in ≥ 2 joints must be present if CRP is used to define flare, CRP must be > 30 mg/L

Inactive disease was defined as meeting all of the following: No joints with active arthritis; No fever (body temperature ≤ 38°C); No rheumatoid rash, serositis, splenomegaly, hepatomegaly or generalized lymphadenopathy attributable to JIA; Normal CRP; Physician's global assessment of disease activity score ≤ 10 mm

To evaluate the percentage of participants with canakinumab treatment who were able to taper corticosteroids successfully over time

To evaluate the change from baseline of corticosteroids dose reduction with canakinumab treatment over time

To evaluate serum concentration (mean, standard deviation) of canakinumab.

To evaluate serum total IL-1 Beta concentration by visit.

To evaluate the percentage of participants with canakinumab treatment who were able to taper corticosteroids successfully at Week 28

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

Adapted ACR Pediatric 30/50/70/90/100 criteria was assessed based on the following 7 variables: 1. Physician's Global Assessment of disease activity on a 0-100 mm VAS; 2. Parent's or Patient's (if appropriate in age) Global Assessment of Patient's overall wellbeing based upon the 0-100 mm VAS in the CHAQ; 3. Functional ability: CHAQ; 4. Number of joints with active arthritis; 5. Number of joints with limitation of motion; 6. Laboratory measure of inflammation: CRP (mg/L); 7. Absence of intermittent fever due to SJIA during the preceding week. Response was defined as more than or equal to (≥) 30%/50%/70%/90% or 100% improvement in at least 3 of 6 response variables and no intermittent fever in the preceding week (variable 7) with no more than one variable 1-6 worsening by more than 30%.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

ACR component, Physician's Global Assessment of disease activity on a 0 - 100 mm VAS by visit is the first response ACR variable in the ACR pediatric criteria. The VAS scale ranges from no disease activity (0 mm) to very severe disease activity (100 mm). Lower scale indicates decreased disease activity. Change from baseline was calculated by subtracting baseline value from post baseline value.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

ACR component, Parent's or Patient's (if appropriate in age)Global Assessment of patient's overall well-being as part of CHAQ on a 0 - 100 mm VAS by visit is the second response variable in the ACR pediatric criteria. The VAS scale ranges from 0-100 mm, from very well (0 mm) to very poor (100 mm). Lower scale indicates improvement of patient's overall well-being. Absolute change is calculated by subtracting baseline value from post baseline value.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

Disability Score as part of CHAQ per functional ability score (range from 0 to 3) is one of the variable in the ACR ped criteria. The CHAQ was used to assess physical ability & functional status of patients as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activity categories of daily living: dressing & grooming, arising, eating, walking, reaching, personal hygiene, gripping & other "activities". Subjects choose from 4 responses, ranging from 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) & 3 (unable to do). Standard Disability Index (SDI) was computed by summing up the computed scores for each activity category and dividing by the number of categories answered. The lower the response the more positive the results & the higher the response, the less positive the results. Change from baseline was calculated by subtracting baseline value from post baseline value.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

ACR component, Number of joints with active arthritis was assessed as the forth response variables of ACR Pediatric Criteria.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

ACR component, Number of joints with limitation of motion is the fifth response variable in the ACR ped criteria.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

ACR component, Number of participants having fever is the seventh response variable in the ACR ped criteria.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

ACR component, Standardized CRP is the sixth response variable in the ACR ped criteria. CRP values were standardized to a normal range of 0 to 10 mg/L.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

Flare was defined by at least 1 of the following: Reappearance of SJIA-related (e.g., not due to infection) fever (> 38°C) lasting for at least 2 consecutive days &/OR Flare according to the JIA pediatric criteria for flare (all criteria must be met): ≥ 30% worsening in at least 3 of the 6 response variables and ≥ 30% improvement in at not more than 1 of the 6 response variables if the physician's or parent's global assessment is 1of 3 response variables used to define flare, worsening of ≥ 20 mm must be present, if the number of active joints or joints with limitation of motion is one of 3 response variables used to define flare, worsening in ≥ 2 joints must be present if CRP is used to define flare, CRP must be > 30 mg/L

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

Inactive disease was defined as meeting all of the following: No joints with active arthritis; No fever (body temperature ≤ 38°C); No rheumatoid rash, serositis, splenomegaly, hepatomegaly or generalized lymphadenopathy attributable to JIA; Normal CRP; Physician's global assessment of disease activity score ≤ 10 mm

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

To evaluate the percentage of participants with canakinumab treatment who were able to taper corticosteroids successfully over time

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

To evaluate the change from baseline of corticosteroids dose reduction with canakinumab treatment over time

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

To evaluate serum concentration (mean, standard deviation) of canakinumab.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.

To evaluate serum total IL-1 Beta concentration by visit.

The FAS consisted of all 19 patients who were enrolled and received at least one dose of canakinumab.